Biomarker for predicting disease recurrence in non-metastatic papillary kidney cancer
A biomarker is a biological molecule found in blood, other [...]
Telaglenastat plus cabozantinib or everolimus for advanced/metastatic kidney cancer
This phase 1 clinical trial looked at the safety, tolerability, [...]
ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer
A gene called MET codes for a protein called MET [...]
Patterns of metastases for clear cell, papillary and chromophobe RCC associated with survival
A recent study published in JAMA Network Open looked at [...]
Everolimus and bevacizumab for advanced papillary kidney cancer
In this phase 2 clinical trial, a combination of everolimus [...]
Immune checkpoint inhibitors for papillary kidney cancer
Papillary renal cell carcinoma (RCC) is a rare form of [...]
Summary from ASCO 2020 virtual meeting
This article nicely summarises the most exciting research highlights from [...]
ASCO 2020: Subtypes of kidney cancer differ in sites of metastases
A paper presented during the 2020 American Society of Clinical [...]
Bone metastases are associated with poor prognosis in papillary kidney cancer
A recent retrospective study looked at the data from 49 [...]
ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC
Results from a phase II study of bevacizumab and erlotinib [...]
